BioPharmSignal logoBioPharmSignal

Biotech News

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

Oculis (OCS)OculisConference / presentation

ZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that

Related news

OCSOculis2026-04-20 08:00 EST

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

SGHTSight Sciences2026-03-30 20:05 EST

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

OKYOOKYO Pharma2026-07-21 13:00 EST

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

HROWHarrow, Inc.2026-05-27 11:00 EST

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

TARSTarsus Pharmaceuticals2026-05-28 20:30 EST

Tarsus to Participate in Upcoming Investor Conferences

BLTEBelite Bio2026-05-15 12:00 EST

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

OKYOOKYO Pharma2026-07-27 11:00 EST

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

OCSOculis2026-08-03 08:00 EST

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

OCSOculis2026-07-08 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Stock data

Close
12.38 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States